These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8394203)

  • 1. Retrospective analysis of prognostic significance of the estrogen-inducible pS2 gene in male breast carcinoma.
    Kardaś I; Seitz G; Limon J; Niezabitowski A; Ryś J; Theisinger B; Welter C; Blin N
    Cancer; 1993 Sep; 72(5):1652-6. PubMed ID: 8394203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure and function of the pS2 gene and estrogen receptor in human breast cancer cells.
    Stack G; Kumar V; Green S; Ponglikitmongkol M; Berry M; Rio MC; Nunez AM; Roberts M; Koehl C; Bellocq P
    Cancer Treat Res; 1988; 40():185-206. PubMed ID: 2908650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of the estrogen regulated pS2 protein in mammary tumors.
    Pichon MF; Milgrom E
    Crit Rev Oncol Hematol; 1993 Aug; 15(1):13-21. PubMed ID: 8240704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PS2 expression in BRCA1-associated breast cancers.
    Charafe-Jauffre E; Eisinger F; Mathoulin-Portier MP; Sobol H; Jacquemier J
    Anticancer Res; 2001; 21(4B):2877-81. PubMed ID: 11712780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pS2 gene, mRNA, and protein: a potential marker for human breast cancer.
    Rio MC; Chambon P
    Cancer Cells; 1990; 2(8-9):269-74. PubMed ID: 2223388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of pS2 protein in breast cancer.
    Crombach G; Ingenhorst A; Göhring UJ; Scharl A; Neuhaus W; Möbus V; Schaeffer HJ
    Arch Gynecol Obstet; 1993; 253(4):183-92. PubMed ID: 8161252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
    Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
    Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of pS2 mRNA in breast cancer.
    Wysocki SJ; Iacopetta BJ; Ingram DM
    Eur J Cancer; 1994; 30A(12):1882-4. PubMed ID: 7880621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers].
    Abadjian G; Antoun R
    J Med Liban; 1996; 44(1):10-5. PubMed ID: 8965315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
    Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
    Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of pS2 messenger RNA in gynecological cancers.
    Wysocki SJ; Hahnel E; Masters A; Smith V; McCartney AJ; Hahnel R
    Cancer Res; 1990 Mar; 50(6):1800-2. PubMed ID: 2306733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [pS2 protein and breast cancer].
    Torre EA; Fulco RA
    Minerva Ginecol; 1995 Dec; 47(12):553-6. PubMed ID: 8720977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors.
    Lu D; Kiriyama Y; Lee KY; Giguère V
    Cancer Res; 2001 Sep; 61(18):6755-61. PubMed ID: 11559547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
    Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
    Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PS2 protein in breast carcinomas: cut-off value of estrogen-regulated expression.
    Nikolić-Vukosavljević D; Grujić-Adanja G; Janković R; Nesković-Konstantinović Z; Branković-Magić M
    Neoplasma; 2001; 48(1):1-6. PubMed ID: 11327531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival.
    Thor AD; Koerner FC; Edgerton SM; Wood WC; Stracher MA; Schwartz LH
    Breast Cancer Res Treat; 1992; 21(2):111-9. PubMed ID: 1627814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of pS2 protein in breast cancer and its relationship with estrogen and progesterone receptors].
    Díez Gibert O; Machuca I; Sebastián MA; Rosel P; Navarro MA
    Med Clin (Barc); 1996 Jun; 107(3):90-2. PubMed ID: 8754494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pS2 protein status fails to be an independent prognostic factor in an average breast cancer population.
    Speiser P; Stolzlechner J; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeilliger R
    Anticancer Res; 1994; 14(5B):2125-30. PubMed ID: 7840511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study].
    Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E
    Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.